BOULDER, Colo., Nov. 16 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. will today present data on its lead oncology drug candidate TPI 287 at the AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia. New in vitro and in vivo studies with TPI 287 support the biological activity of this compound in microtubule protein polymerization, cellular transport, cytotoxicity, as well as KBV drug resistant tumor xenograft model studies.
Data presented indicates that TPI 287 does not exhibit polarized drug transport in Caco-2 and MDCKII-MDR1 tumor cells indicating, among other things, that it is not a substrate for the multiple drug resistance efflux pump, which is believed to be a primary mechanism resulting in the development of resistance in patients being treated with taxanes, and may, in fact, be orally bioavailable. These conclusions are augmented by data showing activity in treatment resistant cell lines characterized by the over expression of MDR1 as well as activity in tumor xenograft models also characterized by an over expression of MDR1.
TPI 287 is a third-generation taxane designed to overcome resistance caused by the MDR1 efflux pump as well as mutant tubulin. The drug candidate is in two Phase I trials studying its safety in intravenous administration in different dosing regimens. Tapestry expects to study TPI 287 in Phase II trials in multiple tumor types beginning in the second half of 2006. Additional non-clinical experiments studying the viability of TPI 287 in an oral formulation are ongoing and Tapestry expects to make a decision about whether to initiate clinical studies with an oral form of the drug sometime in the next year.
“We are very pleased with this molecule’s breadth and specificity of tumor response to date; its progress in Phase I trials; and its potential as an orally bioavailable taxane,” commented Leonard Shaykin, Chairman and Chief Executive Officer.
Biological Characterization of TPI 287 a Novel Third Generation Taxane Analog Abstract and Poster, No. B232 are scheduled for presentation at 12:30 PM - 2:30 PM and at 5:30 PM - 7:30 PM (Poster Session B) on Wednesday, November 16, 2005.
About Tapestry Pharmaceuticals, Inc.
Tapestry Pharmaceuticals, Inc. is a company focused on the development of proprietary therapies for the treatment of cancer.
For more information about Tapestry and its technologies, visit Tapestry’s web site at www.tapestrypharma.com.
Forward Looking Statements
Statements in this press release that are not historical facts are “forward-looking statements” that involve risks and uncertainties. Forward-looking statements can be identified by the use of words such as “opportunities,” “trends,” “potential,” “estimates,” “may,” “will,” “should,” “anticipates,” “expects” or comparable terminology or by discussions of strategy. Such forward looking statements include statements relating to the clinical development program for TPI 287, the safety and effectiveness of TPI 287, the ability of TPI 287 to overcome drug resistance, and the potential of TPI 287 as an orally administered compound. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include risks that Tapestry will be unable to manufacture additional TPI 287 according to GMP standards or in sufficient quantities to complete clinical trials; that clinical trials for TPI 287 will be delayed due to institutional approvals, patient recruitment, formulation and manufacturing difficulties or other factors; that additional studies will show that TPI 287 is not suitable for oral administration, and that human clinical trials may show that TPI 287 is unsafe and/or ineffective in treating cancer in human patients. General implementation risks associated with development of any of our products include those that we are blocked or limited in the development of our product candidates because of the intellectual property rights of third parties; that we are limited in our ability to obtain, maintain and enforce our own intellectual property; that development of our product candidates is delayed or terminated because the costs of further development exceed the value of such candidates; and that the Company’s resources are insufficient to continue development and the Company will be unable to raise sufficient additional capital to continue operations and development. Additional risks, uncertainties and other factors are identified under the captions “Risk Factors” and “Special Note Regarding Forward-Looking Statements” in the Company’s reports filed from time to time with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.
For further information, please contact Gordon Link, Senior Vice President, Chief Financial Officer, at 303 516 8500.
Tapestry Pharmaceuticals, Inc.
CONTACT: Gordon Link, Senior Vice President, Chief Financial Officer ofTapestry Pharmaceuticals, Inc., +1-303-516-8500, glink@tapestrypharma.com;or Investors, Michael Wachs of CEOcast, Inc., +1-212-732-4300, for TapestryPharmaceuticals, Inc.; or Media, Peter Steinerman, +1-516-374-3031, forTapestry Pharmaceuticals, Inc.
Web site: http://www.tapestrypharma.com/
